À	
- 1	

U.S. DEPARTMENT OF COMMERCE PATENT AND TRADEMARK OFFICE

ATTY. DOCKET NO. 065691/0216 SERIAL NO.

Unassigne

**APPLICANT** 

**FILING DATE** 

Jean-Claude CHERMANN et al.

**GROUP ART UNIT** 

(Use several sheets if necessary)

INFORMATION DISCLOSURE CITATION

Form PTO-1449 (MODIFIED)

6/06/2001

Unassigne

U.S. PATENT	DOCUMENTS
-------------	-----------

EXAMINER INITIAL	REF	DOCUMENT NUMBER	DATE	NAME	CLASS	SUB- CLASS	FILING DATE IF APPROPRIATE
	A1	5,733,550	03/98	Rock	424	185.1	

## **FOREIGN PATENT DOCUMENTS**

REF	DOCUMENT	DATE COUNTRY	COUNTDY	CLASS	SUB-	TRANSLATION		
	NUMBER		CLASS	CLASS	YES	NO		
W	A2	0 229 723	07/87	EPA	C 07 K	13/00		
	A3	94/24290	10/94	WIPO				
	A4	92/18630	10/92	WIPO		-		
	A5	94/01130	01/94	WIPO				
1	A6	93/14126	07/93	WIPO				
00	A7	0 229 723	07/87	EUROPE				

## OTHER DOCUMENTS (Including Author, Title, Date, Pertinent Pages, Etc.)

\ <b>\</b> \\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\		Contel et al., "Identification of the β2m derived epitope responsible for neutralization of HIV isolates",				
A8	A8	Cellular Pharmacology, Vol. 3:68-73, (1996)				
,	A9	Haynes et al., "Update on the issues of theHIV vaccine development", Ann. Med. Vol. 28: pp. 39-41, 1996				
	A10	Baltimore et al., "Defeating AIDS: what will it take?", Scientific American. Pp. 81-107, 1998				

**EXAMINER** 

DATE CONSIDERED

EXAMINER: Initial if citation considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include any copy of this form with next communication to applicant.